Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study

Jasper J. Twilt, Anindo Saha, Joeran S. Bosma, Bram van Ginneken, Anders Bjartell, Anwar R. Padhani, David Bonekamp, Geert Villeirs, Georg Salomon, Gianluca Giannarini, Jayashree Kalpathy–Cramer, Jelle O. Barentsz, Klaus Maier‐Hein, Mirabela Rusu, Olivier Rouvière, Roderick van den Bergh, Valeria Panebianco, Veeru Kasivisvanathan, Nancy A. Obuchowski, Derya Yakar, Mattijs Elschot, Jeroen Veltman, Jurgen J. Fütterer, Henkjan Huisman, Maarten de Rooij, Constant R. Noordman, Ivan Slootweg, Christian Roest, Stefan J. Fransen, Mohammed R.s. Sunoqrot, Tone F. Bathen, Dennis Rouw, Jeroen Geerdink, Chris van Run, Miriam Groeneveld, James Meakin, Jos J.f.m. Immerzeel, Jayashree Kalpathy-Cramer, Klaus H. Maier-Hein, Afsoun Malakoti-Fard, Agnė Mačiūnien, Akira Kawashima, Ana M. Gaivão, Ana S.l. Moreira, Andrea Ponsiglione, Annelies Rappaport, Arnaldo Stanzione, Arturas Ciuvasovas, Baris Turkbey, Bart De Keyzer, Bodil G. Pedersen, Bram Eijlers, Christine Chen, Ciabattoni Riccardo, Deniz Alis, Ewout F.w. Courrech Staal, Erik Thimansson, Fredrik Jäderling, Fredrik Langkilde, Giacomo Aringhieri, Giorgio Brembilla, Hannah Son, Hans van der Lelij, Henricus P.j. Raat, Ingrida Pikūnienė, Iva Macova, Ivo Schoots, Iztok Caglic, Jeries P. Zawaideh, Jonas Wallström, Leonardo K. Bittencourt, Misbah Khurram, Moon Hyung Choi, Naoki Takahashi, Nelly Tan, Paolo N. Franco, Patricia A. GutierrezEuropean 2024 · DOI

TL;DR

This large international study found that biparametric MRI (bpMRI), a shorter protocol without contrast agents, is as effective as the standard multiparametric MRI (mpMRI) for diagnosing clinically significant prostate cancer. This suggests bpMRI could streamline prostate cancer diagnosis, increasing patient throughput and access to this crucial imaging modality.

What Problem Does This Paper Address?

Prostate cancer diagnosis often relies on magnetic resonance imaging (MRI). The standard approach, multiparametric MRI (mpMRI), involves multiple sequences, including dynamic contrast-enhanced (DCE) imaging. However, DCE imaging adds time, cost, and patient discomfort, and its role is increasingly debated. Biparametric MRI (bpMRI), which omits DCE, has shown promise in smaller studies, but its generalizability and noninferiority to mpMRI in a large, diverse, international setting remained to be confirmed. This study aimed to definitively assess whether bpMRI is a viable, non-inferior alternative to mpMRI for diagnosing clinically significant prostate cancer (csPCa).

Methods

The researchers conducted a large-scale, international, multireader, multicase observer study. 62 radiologists from 45 centers evaluated 400 prostate MRI examinations. Crucially, they performed a paired, sequential assessment: first, they evaluated the images using a biparametric protocol (T2-weighted and diffusion-weighted imaging), assigning PI-RADS scores. Then, they were unblinded to the dynamic contrast-enhanced (DCE) sequence and reassessed the images using the full multiparametric protocol. This design allowed for a direct comparison of diagnostic performance between the two protocols. The reference standard for diagnosing csPCa was histopathology combined with at least three years of follow-up data. Statistical analyses focused on comparing the area under the receiver operating characteristic curve (AUROC), sensitivity, and specificity at various PI-RADS thresholds.

Datasets

The study utilized a dataset of 400 prostate MRI examinations collected between 2015 and 2021 from four European care centers: Radboud University Medical Center, Ziekenhuisgroep Twente, Prostaat Centrum Noord-Nederland, and St. Olav's Hospital. These examinations were from men with a suspicion of prostate cancer, characterized by elevated PSA levels and/or abnormal digital rectal examination findings. Patients with prior prostate treatment or prior csPCa findings were excluded.

Key Insights and Ideas

  • bpMRI is a strong contender: The most significant takeaway is that bpMRI performs comparably to mpMRI for diagnosing clinically significant prostate cancer. This challenges the necessity of DCE in many routine cases.
  • DCE's limited added value for non-experts: While DCE might offer some benefit, it appears to be marginal, especially for radiologists with less experience. This suggests that training and standardization of bpMRI interpretation could be a more impactful area for improving diagnostic accuracy across the board.
  • Thresholds matter for decision-making: Decision curve analyses revealed that the optimal imaging pathway (bpMRI vs. mpMRI) and PI-RADS threshold for biopsy decisions depend on the patient's risk tolerance and willingness to undergo biopsies. In cancer-averse scenarios, mpMRI might offer a slight edge, but bpMRI becomes more favorable when prioritizing fewer biopsies.

Key Results

  • Noninferiority confirmed: bpMRI demonstrated noninferior diagnostic performance to mpMRI in terms of AUROC (0.853 vs. 0.859, a difference of -0.6%).
  • Similar sensitivity and specificity: At the PI-RADS ≥3 threshold, bpMRI showed sensitivity of 88.6% and specificity of 58.6%, very close to mpMRI's 89.4% sensitivity and 57.7% specificity.
  • Trade-offs at different thresholds: At higher PI-RADS thresholds (e.g., ≥4), mpMRI offered slightly higher sensitivity but at the cost of increased false positives compared to bpMRI.
  • Expert vs. Non-expert performance: Expert readers generally performed better than non-experts for both bpMRI and mpMRI, but the difference in performance gain from DCE was minimal between the groups.

Limitations and Future Work

The authors acknowledge several limitations:

  • Verification bias: Biopsies were guided by mpMRI, which could introduce bias in the reference standard.
  • Sequential reading: The sequential reading of bpMRI followed by mpMRI might have introduced a bias, though it mimics clinical practice.
  • Exclusion criteria: Patients with prior treatment or severe artifacts were excluded, potentially underestimating DCE's value in these specific scenarios.
  • Reader expertise: The majority of readers were experts, and studies were often from high-throughput centers, which might limit generalizability to less experienced readers or lower-volume centers.

Future work should focus on:

  • Prospective studies: Large-scale, prospective, randomized trials are needed to validate these findings and assess the impact of bpMRI on clinical decision-making, particularly regarding biopsy strategies.
  • PI-RADS v2.1 evaluation: Further evaluation of the PI-RADS v2.1 scoring system for bpMRI, potentially integrating quantitative MRI and AI, could enhance its accuracy.
  • Real-world implementation: Investigating the practical implementation of bpMRI in routine clinical practice, including its impact on patient throughput and cost-effectiveness, is crucial.

Summary updated

Abstract

It has been found that bpMRI is noninferior to mpMRI in csPCa diagnosis at AUROC, along with the sensitivity and specificity at PI-RADS ≥3, showing its value in individuals without prior csPCa findings and prostate treatment. Additional randomized prospective studies are required to investigate the generalizability of outcomes.
BibTeX
@inproceedings{twilt2024evaluating,
  author = {Jasper J. Twilt and Anindo Saha and Joeran S. Bosma and Bram van Ginneken and Anders Bjartell and Anwar R. Padhani and David Bonekamp and Geert Villeirs and Georg Salomon and Gianluca Giannarini and Jayashree Kalpathy–Cramer and Jelle O. Barentsz and Klaus Maier‐Hein and Mirabela Rusu and Olivier Rouvière and Roderick van den Bergh and Valeria Panebianco and Veeru Kasivisvanathan and Nancy A. Obuchowski and Derya Yakar and Mattijs Elschot and Jeroen Veltman and Jurgen J. Fütterer and Henkjan Huisman and Maarten de Rooij and Jasper J. Twilt and Anindo Saha and Joeran S. Bosma and Bram van Ginneken and Constant R. Noordman and Ivan Slootweg and Christian Roest and Stefan J. Fransen and Mohammed R.S. Sunoqrot and Tone F. Bathen and Dennis Rouw and Jeroen Geerdink and Chris van Run and Miriam Groeneveld and James Meakin and Jos J.F.M. Immerzeel and Derya Yakar and Mattijs Elschot and Jeroen Veltman and Jurgen J. Fütterer and Maarten de Rooij and Henkjan Huisman and Anders Bjartell and Anwar R. Padhani and David Bonekamp and Geert Villeirs and Georg Salomon and Gianluca Giannarini and Jayashree Kalpathy-Cramer and Jelle Barentsz and Klaus H. Maier-Hein and Mirabela Rusu and Nancy A. Obuchowski and Olivier Rouviere and Roderick van den Bergh and Valeria Panebianco and Veeru Kasivisvanathan and Afsoun Malakoti-Fard and Agnė Mačiūnien and Akira Kawashima and Ana M. Gaivão and Ana S.L. Moreira and Andrea Ponsiglione and Annelies Rappaport and Arnaldo Stanzione and Arturas Ciuvasovas and Baris Turkbey and Bart De Keyzer and Bodil G. Pedersen and Bram Eijlers and Christine Chen and Ciabattoni Riccardo and Deniz Alis and Ewout F.W. Courrech Staal and Erik Thimansson and Fredrik Jäderling and Fredrik Langkilde and Giacomo Aringhieri and Giorgio Brembilla and Hannah Son and Hans van der Lelij and Henricus P.J. Raat and Ingrida Pikūnienė and Iva Macova and Ivo Schoots and Iztok Caglic and Jeries P. Zawaideh and Jonas Wallström and Leonardo K. Bittencourt and Misbah Khurram and Moon Hyung Choi and Naoki Takahashi and Nelly Tan and Paolo N. Franco and Patricia A. Gutierrez},
  title = {{Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study}},
  booktitle = {European},
  year = {2024},
  doi = {10.1016/j.eururo.2024.09.035},
}
Figure